Research Analysts Offer Predictions for ACRS Q3 Earnings

Posted by George Bondi on Aug 12th, 2026

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Equities research analysts at HC Wainwright cut their Q3 2026 EPS estimates for Aclaris Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.15) per share for the quarter, down from their prior estimate of ($0.11). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.60) EPS.

A number of other research firms have also commented on ACRS. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday, June 24th. Guggenheim began coverage on Aclaris Therapeutics in a research report on Tuesday, May 5th. They set a “buy” rating and a $12.00 target price for the company. Lifesci Capital initiated coverage on Aclaris Therapeutics in a report on Tuesday, June 2nd. They set an “outperform” rating and a $13.00 target price on the stock. Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, UBS Group set a $10.00 price target on Aclaris Therapeutics in a research report on Thursday, April 16th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Buy” and an average target price of $11.50.

Read Our Latest Report on ACRS

Aclaris Therapeutics Trading Up 0.3%

Shares of ACRS stock opened at $5.92 on Wednesday. The stock has a market cap of $827.73 million, a P/E ratio of -10.21 and a beta of 0.78. The stock has a 50 day simple moving average of $5.19 and a 200 day simple moving average of $4.36. Aclaris Therapeutics has a 1 year low of $1.58 and a 1 year high of $6.51.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The company had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.38 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ACRS. Bank of New York Mellon Corp boosted its position in Aclaris Therapeutics by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock valued at $776,000 after buying an additional 3,507 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Aclaris Therapeutics by 2.2% during the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock worth $539,000 after buying an additional 6,217 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Aclaris Therapeutics by 7.4% during the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,271 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Aclaris Therapeutics by 45.4% during the fourth quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock worth $65,000 after buying an additional 6,734 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Aclaris Therapeutics by 19.8% during the fourth quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock worth $140,000 after buying an additional 7,702 shares in the last quarter. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics News Summary

Here are the key news stories impacting Aclaris Therapeutics this week:

Positive Sentiment: Wall Street’s consensus price target indicates approximately 69.2% potential upside for ACRS. The report notes that estimate revisions can be more useful than price targets, but the sizable implied upside remains a potential source of investor interest. Wall Street Analysts Believe Aclaris Could Rally 69.2%
Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period. Because the data show no measurable short position, short-covering activity is unlikely to be a meaningful near-term catalyst.
Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.62 from $0.49 and reduced its FY2027 forecast to a loss of $0.60 from $0.51. The firm also cut estimates for multiple quarters, including Q3 2026 to $(0.15) from $(0.11), Q4 2026 to $(0.16) from $(0.10), and Q1 2027 to $(0.15) from $(0.11). These revisions point to weaker expected profitability and could pressure the stock.

About Aclaris Therapeutics

(Get Free Report)

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.